Octreotide is used to treat a variety of conditions, including:
In addition to these, octreotide is also used to manage symptoms related to other hormone-secreting tumors .
Octreotide was approved for medical use in the United States in 1988 . It is available under various brand names, including Sandostatin, Bynfezia Pen, and Mycapssa . Notably, Mycapssa is the first and only oral somatostatin analog approved by the FDA for long-term maintenance treatment of acromegaly .
The bioavailability of octreotide varies depending on the route of administration, with 60% bioavailability when administered intramuscularly and 100% when administered subcutaneously . It has a protein binding rate of 40-65% and is metabolized primarily in the liver . The elimination half-life of octreotide ranges from 1.7 to 1.9 hours, and it is excreted mainly through urine (32%) .